CN105287531A - Anti-diabetic orally-administered pharmaceutical composition - Google Patents
Anti-diabetic orally-administered pharmaceutical composition Download PDFInfo
- Publication number
- CN105287531A CN105287531A CN201510764566.6A CN201510764566A CN105287531A CN 105287531 A CN105287531 A CN 105287531A CN 201510764566 A CN201510764566 A CN 201510764566A CN 105287531 A CN105287531 A CN 105287531A
- Authority
- CN
- China
- Prior art keywords
- base
- diabetic
- pharmaceutical composition
- insulin
- chromene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an anti-diabetic pharmaceutical composition which comprises (1) 10-20 mg of 5-(3-hydroxyl-7-propoxynaphthalene-2-yl-1,1-dioxo-[1,2,5]thiadiazole alkyl-3-ketone potassium salt, (2) 20-30 mg of 2-((3S)-7-(2',6'-dimethyl -[1,1'-biphenyl)-3-yl)-3,5,6,7-tetrahydro-2H-furo[3,2-g]chromene-3-yl)acetic acid, (3) 200-300 mg of microcrystalline cellulose, (4) 10-25 mg of croscarmellose sodium and (5) 1-8 mg of magnesium stearate. According to the anti-diabetic orally-administered pharmaceutical composition, through the compounding of two different types of active matter, on the premise of achieving the same therapeutic effect, the usage amount of the active matter of the medicine is reduced by at least 1/2.
Description
Technical field
The present invention relates to medical art, be specifically related to a kind of diabetes combination of oral medication.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature.Hyperglycemia be then due to defect of insulin secretion or its biological agent impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.
The generally acknowledged form of usual existence two kinds of diabetes.In type 1 diabetes or insulin-dependent diabetes (IDDM), patient produces seldom or does not have insulin, regulates the hormone of glucose application.In type 2 diabetes mellitus or noninsulindependent diabetes (NIDDM), still produce insulin in the body.There is in the stimulation glucose of the patient suffering from type 2 diabetes mellitus in main insulin-sensitive tissue (it is muscle, liver and fatty tissue) and lipid metabolism the toleration to insulin action.These patients have the insulin of common level usually, and may have hyperinsulinemia (plasma insulin level of rising), because they compensate by the insulin of secretion rise the insulin effects reduced.Insulin resistance can not be caused by the Insulin receptor INSR reducing quantity but be caused by the rear Insulin receptor INSR binding deficient understood not yet completely substantially.This lacks and to cause in the oxidation of glucose in the activation of the insulin-mediated of inadequate picked-up, muscle and storage and fatty tissue glucose in lipidolysis and liver to produce to the responding ability of insulin and the suppression of insufficient insulin-mediated of secretion.
Current Remedies for diabetes is maintaining treatment effect, many employing 100mg active matter oral doses, and needs daily repeatedly to take.Due to the side effect of active matter, other health hazards are caused to patient, meanwhile, due to the increase of dosage, also make medicine cost increase, cause the raising for the treatment of cost.
Summary of the invention
The object of the invention is to propose a kind of diabetes combination of oral medication, its composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2.
For reaching this object, the present invention by the following technical solutions:
A kind of diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 2-((3S)-7-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3, the 2-g] chromene-3-base) acetic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
Described 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and 2-((3S)-7-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3,2-g] chromene-3-base) ratio of acetic acid is less than 1.
Detailed description of the invention
The present invention is described pharmaceutical composition of the present invention by following embodiment.
Embodiment 1
I.5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
Step 1
3-hydroxyl-7-propoxyl group naphthalene-2-propyl formate
3.0g (14.7mmol) 3,7-dihydroxy naphthlene-2-formic acid is added in the suspension of 1.6g (29.6mmol) Feldalat NM in DMA (30mL).By mixture in stirring at room temperature 1 hour, then add 5.05g (29.7mmol) propyl iodide, continue stirring 48 hours.By in mixture impouring water, use 2NHCl acidify.Be extracted with ethyl acetate mixture, by (3 ×) water and saline (1 ×) washing organic facies.Use dried over sodium sulfate solution, under reduced pressure except desolventizing.Residual oil thing carries out purification by flash chromatography dichloromethane, elutes title compound, isolates as yellow oil.MS(M-1)：287。
Step 2
3-benzyloxy-7-propoxyl group naphthalene-2-propyl formate
0.98g (5.73mmol) benzyl bromide a-bromotoluene is added in 1.5g (5.21mmol) 3-hydroxyl-7-propoxyl group naphthalene-2-propyl formate and the mixture of 1.08g (7.81mmol) potassium carbonate in DMF (15mL).By mixture in stirring at room temperature 48 hours, then in impouring water.Be extracted with ethyl acetate mixture, wash organic facies with water (3x) and saline (1x).Use dried over sodium sulfate solution, under reduced pressure except desolventizing.Residual oil thing uses dichloromethane to carry out purification by flash chromatography, elutes title compound, is separated into yellow oil.
Step 3
3-benzyloxy-7-propoxyl group naphthalene-2-formic acid
In the solution of 680mg (1.8mmol) 3-benzyloxy-7-propoxyl group naphthalene-2-propyl formate in EtOH (15mL), add 2.0mL1.0NNaOH, then mixture is stirred 3 hours in 60 DEG C.Under reduced pressure except desolventizing, residual solid is soluble in water.Use MTBE wash solution, with 1NHCl acidify aqueous phase.Filtration gained precipitates, and washing with water, drying under reduced pressure, obtain title compound, is white solid, mp125-128 ° of .MS (M-1): 335.
5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
In accordance with known methods, title compound is obtained, mp250-255 ° by 3-benzyloxy-7-propoxyl group naphthalene-2-formic acid.
1h-NMR (DMSO-d6: δ 7.88 (s, 1H), 7.54 (d, J=9.04Hz, 1H), 7.13 (s, 1H), 7.12 (d, J=2.64Hz, 1H), 6.98 (dd, J=9.04 and 2.64Hz, 1H), 4.19 (s, 2H), 3.98 (t, 2H), 1.75 (m, 2H), 1.00 (t, 3H) .MS (M-1): 335.
II.2-((3S)-7-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3,2-g] chromene-3-base) acetic acid
Steps A: (S)-2-(2-phenyl-6,7-dihydro-4H-[1,3,2] dioxa bora cyclohexene is [5,4-f] benzofuran-6-base also) methyl acetate.
To (S)-2-(6-hydroxyl-2,3-Dihydrobenzofuranes-3-base) methyl acetate (3.00g, 14.4mmol), phenylboric acid (2.11g, 17.3mmol), propanoic acid (0.539ml, 7.20mmol) is added with in benzene (25mL) serosity of paraformaldehyde (3.46g, 115mmol).By subsidiary for DeanStarktrap in flask, then gained mixture is heated to backflow.After 4h, this reaction is cooled to room temperature.Remove homogeneous solution to provide crude product, it passes through HPLC (ISCO0 to 100%EtOAc/Hex) purification to provide title compound.
1HNMR(500MHz，CDCl
3)δ7.50-7.40(m，5H)，6.81(s，1H)，6.60(s，1H)，5.10（s，2H)，4.80(t，1H)，4.31(dd，1H)，3.84(m，1H)，3.79(s，3H)，2.79(dd，1H)，2.62(dd，1H).
Step B:2-((3S)-7-(3-bromo phenyl)-3,5,6,7-tetrahydrochysene-2H-furo [3,2-g] chromene-3-base) methyl acetate.
The bromo-3-vinyl benzene of clean merging 1-(1000mg in sealed tube, 5.46mmol) with (S)-2-(2-phenyl-6,7-dihydro-4H-[1,3,2] dioxa bora cyclohexene also [5,4-f] benzofuran-6-base) methyl acetate (200mg, 0.617mmol).Then, this mixture is heated to 200 DEG C.After 2h, this reaction is cooled to room temperature and by HPLC (ISCO0 to 50%EtOAc/Hex) Purification to provide title compound.
1HNMR(500MHz，CDCl
3)δ7.60(s，1H），7.46(d，1H)，7.38(d，1H)，7.28(d，1H)，6.88(s，1H)，6.40(s，1H)，5.00(d，1H)，4.77(t，1H)，4.23(m，1H)，3.80(m，1H)，3.75(s，3H)，2.90(m，1H)，2.78(m，2H)，2.60(dd，1H)，2.20(m，1H).
Step C:2-((3S)-7-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3,2-g] chromene-3-base) methyl acetate.
To (2,6-3,5-dimethylphenyl) boric acid (22mg, 0.15mmol), 2-((3S)-7-(3-bromo phenyl)-3,5,6,7-tetrahydrochysene-2H-furo [3,2-g] chromene-3-base) methyl acetate (40mg, 0.10mmol), and in toluene (0.50mL) solution that purges of the nitrogen of tetrakis triphenylphosphine palladium (0) (5.7mg, 5.0 μm of ol) add KCO solution (2N is in water, 0.1mL, 0.20mmol).Gained mixture is heated to 100 DEG C by heat block.After 12h, this reaction is cooled to room temperature, then pours in NHCl (sat, aq, 10mL) also with EA (2x10mL) extraction.The organic layer drying (MgSO) that merges is concentrated.By HPLC (ISCO0 to 50%EtOAc/Hex) purification gained residue to provide title compound.
1HNMR(500MHz，CDCl
3)δ7.50-7.40(m，2H)，7.22-7.10(m，5H)，6.85(s，1H)，6.40(s，1H)，5.10(d，1H)，4.75(t.1H)，4.22(t，1H)，3.81(m，1H)，3.75(s，3H)，2.92(m，1H)，2.75(m，2H)，2.60(m，1H)，2.22(m，1H)，2.10(m，1H)，2.05(d，6H).
To 2-((3S)-7-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3,2-g] chromene-3-base) methyl acetate (40mg, LiOH (22.35mg, 0.933mmol) is added in THF/ water/MeOH solution 0.093mmol).Then, this mixture is heated to 60 DEG C by heat block.After 12h, this reactant mixture is poured in 1NHCl (10mL) also with EtOAc (2x10mL) extraction.The organic layer drying (MgSO) that merges is concentrated.By HPLC (ISCO, 24g, 0 to 100%EA/hex) purification gained residue to provide title compound.
1HNMR(500MHz，CDCl
3)δ7.49-7.40(m，2H)，7.21-7.10(m，5H)，6.90(s，1H），6.40（s，1H），5.10(d，1H)，4.78(t，1H)，4.29(t.1H)，3.80(m，1H），2.95(m，1H)，2.82(dd，1H)，2.75(dt，1H)，2.64(m，1H)，2.22(m，1H)，2.08(m，1H)，2.02(d，6H).
By the component I for preparing and II, obtain described diabetes combination of oral medication according to following dosage is composite:
(1) 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 15mg
(2) 2-((3S)-7-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3, the 2-g] chromene-3-base) acetic acid of 30mg
(3) 268mg microcrystalline Cellulose,
(4) 20mg cross-linking sodium carboxymethyl cellulose, and
(5) 5mg magnesium stearate.
The bull C57BLob/ob mice in 11 week age is housed in reverse smooth circular chamber (from 6:00p.m. to 6:00a.m. illumination) with 6/cage, arbitrarily edible Purina Rodent Meal and drinking-water.At the 1st day, get tail blood sample at 8:00am, measure plasma glucose levels.Animal is randomized into matched group and compound group.The meansigma methods of the plasma glucose levels of each group is mated.Then the Orally administered solvent of animal (there is 0.5% carboxymethyl cellulose of 0.2% tween 80) or the compound (30mg/kg) in solvent is given.Every day, to mice administration, amounts to 3 days.At the 4th day, get basal blood specimens.Adopt the concentration of glucose of YSI2700 dual pathways biochemistry analyzer (YellowSpringsInstrumentCo., YellowSprings, OH) analysed for plasma sample, adopt ELISA algoscopy to measure insulin concentration.Test result shows, its concentration of glucose is 80-120mg/dL, its insulin concentration: 4.4 ~ 8.0mmol/L.
Comparative example 1
Containing the component I of 100mg, not containing component I I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 2
Containing the component I of 50mg, not containing component I I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Comparative example 3
Containing the component I I of 100mg, not containing component I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 4
Containing the component I I of 50mg, not containing component I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Above-described embodiment and comparative example explanation, diabetes combination of oral medication of the present invention, it is composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2, when two kinds of active matters that the present invention adopts are used alone, within the scope of equal volume, glucose in blood cannot be reduced in normal range of the present invention, prove to create cooperative effect between two kinds of active matters that the present invention adopts.
Applicant states, the present invention illustrates diabetes combination of oral medication of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned specific components and formula, does not namely mean that the present invention must rely on above-mentioned detailed component and formula could be implemented.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of each raw material of product of the present invention, all drops within protection scope of the present invention and open scope.
Claims (2)
1. a diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 2-((3S)-7-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3, the 2-g] chromene-3-base) acetic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
2. diabetes combination of oral medication as claimed in claim 1, it is characterized in that, described 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and 2-((3S)-7-(2 ', 6 '-dimethyl-[1,1 '-biphenyl]-3-base)-3,5,6,7-tetrahydrochysene-2H-furo [3,2-g] chromene-3-base) ratio of acetic acid is less than 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510764566.6A CN105287531A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetic orally-administered pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510764566.6A CN105287531A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetic orally-administered pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105287531A true CN105287531A (en) | 2016-02-03 |
Family
ID=55185821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510764566.6A Pending CN105287531A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetic orally-administered pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287531A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
-
2015
- 2015-11-11 CN CN201510764566.6A patent/CN105287531A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
Non-Patent Citations (2)
| Title |
|---|
| 杨玺: "《糖尿病合理用药》", 30 November 2007, 科学技术文献出版社 * |
| 陈培丰等: "《中西医结合临床内科学》", 31 August 2006, 浙江科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI749024B (en) | Compounds and their use for reducing uric acid levels | |
| JP2007099764A (en) | Hypoglycaemic agent | |
| TW201121544A (en) | Novel phenol derivative | |
| CN102917705A (en) | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases | |
| MX2013012520A (en) | Novel 3-hydroxyisothiazole 1-oxide derivative. | |
| US20160008385A1 (en) | Adrenomedullin production enhancer | |
| TW202102473A (en) | Heterocyclyl (phenyl) methanol compounds useful in the treatment of hyperglycaemia | |
| JP2020520949A5 (en) | ||
| CN105287531A (en) | Anti-diabetic orally-administered pharmaceutical composition | |
| CN105287533A (en) | Anti-diabetes oral pharmaceutical composition | |
| CN105232543A (en) | Anti-diabetic oral drug composition | |
| CN105213386A (en) | A kind of diabetes combination of oral medication | |
| CN105232545A (en) | Antidiabetic oral drug composition | |
| WO2022111493A1 (en) | Pharmaceutical use of complex of arb metabolite and nep inhibitor in prevention and/or treatment of nephropathy | |
| CN105412095A (en) | Anti-diabetes oral drug composition | |
| CN105287532A (en) | Anti-diabetic orally-administered pharmaceutical composition | |
| CN105250276A (en) | Orally-administered drug composition for resisting to diabetes | |
| CN105193801A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN105213385A (en) | A kind of diabetes combination of oral medication | |
| CN105232547A (en) | Anti-diabetic oral drug composition | |
| CN105193821A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN105232544A (en) | Anti-diabetic oral drug composition | |
| WO2015178683A1 (en) | Pharmaceutical composition comprising p-glycoprotein inhibitor and p-glycoprotein substrate drug | |
| CN105213383A (en) | A kind of diabetes combination of oral medication | |
| CN105287534A (en) | Anti-diabetes oral pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |